Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany

Coronary heart disease (CHD) remains the leading cause of death in Germany despite statin use to reduce low-density lipoprotein cholesterol (LDL-C) levels; improving lipids beyond LDL-C may further reduce cardiovascular risk. A fixed-dose combination of extended-release niacin (ERN) with laropiprant...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Michailov, Galin V., Davies, Glenn M., Krobot, Karl J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2011
Témata:
Original Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3343242/
https://ncbi.nlm.nih.gov/pubmed/21465286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10198-011-0309-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky